Study of a new treatment for advanced tumors with low oxygen
Part of Cancer clinical trials.
This trial tests a new drug that targets tumors with a specific marker you can see on a PET scan. It is for people whose cancer has spread or come back after standard treatments, and it may help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 80 years old.
- Your cancer must be confirmed by a biopsy or surgery.
- Your cancer has spread or cannot be removed, and it has worsened after standard treatments like chemo or radiation.
- You must be expected to live more than 6 months.
- Your baseline scan shows high uptake on the NI-FAPI imaging agent.
- You must have adequate organ function and blood counts (checked by blood tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of imaging scan and treatment for cancers that have spread. You would first have two special scans, then you may receive a targeted radiation therapy (177Lu-FAPI-RGD) to see if it can help shrink tumors.
This trial tests a new radioactive drug, [177Lu]Lu-XT117, that seeks out and delivers radiation to solid tumors that have a specific marker called FAP. It's for people whose cancer has not responded to other treatments or who have no other options.
This trial tests a new radioactive treatment (177Lu-CTR-FAPI) that targets a protein on thyroid cancer cells. It's for people whose thyroid cancer has stopped responding to standard treatments, including radioactive iodine and targeted therapies.
This trial tests a new radioactive drug (225Ac-FAPI-XT) for people with advanced solid tumors that have stopped responding to standard treatments. It targets a protein called FAP found on many cancer cells, which may help deliver radiation directly to the tumor.
This trial tests an investigational drug called [177Lu]Lu-XT117, which delivers a small dose of radiation directly to cancer cells that have a specific protein called FAP. It is for people with advanced solid tumors who have run out of standard treatment options or cannot tolerate them.
This trial tests a radioactive drug called 177Lu-CTR-FAPI for people with advanced solid tumors that have not responded to standard treatments. It targets tumors that show a specific protein (FAP) on PET scans. The study focuses on certain cancers like pancreatic, breast, and soft tissue sarcoma.
Hear when a new Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.